Banerjee D K, McDermott-Lancaster R D
Department of Medical Microbiology, St. George's Hospital Medical School, London, U.K.
Int J Lepr Other Mycobact Dis. 1990 Dec;58(4):690-6.
The possibility of synergy between immunotherapy with recombinant interferon-gamma (IFN-gamma) and chemotherapy with rifampin (RMP) and dapsone (DDS) against Mycobacterium leprae was examined in nude mice. IFN-gamma alone failed to show any effect on the growth of M. leprae in the nude mouse foot pad. No synergy was demonstrable between DDS, either at 0.0001% or at 0.001%, and IFN-gamma. A subinhibitory level of RMP with IFN-gamma was also ineffective, but RMP at 0.006% with IFN-gamma produced a statistically significant enhancement of killing (26-fold) when compared with RMP at 0.006% only. It should be emphasized, however, that results obtained in the immunodeficient nude mouse model may not be comparable to those which might have been given by lepromatous leprosy patients.
在裸鼠中研究了重组干扰素-γ（IFN-γ）免疫疗法与利福平（RMP）和氨苯砜（DDS）化疗联合对抗麻风分枝杆菌的协同作用可能性。单独使用IFN-γ对裸鼠足垫中麻风分枝杆菌的生长未显示任何影响。0.0001%或0.001%的DDS与IFN-γ之间未显示协同作用。RMP与IFN-γ的亚抑制水平也无效，但0.006%的RMP与IFN-γ联合使用时，与仅使用0.006%的RMP相比，杀菌作用有统计学显著增强（26倍）。然而，应该强调的是，在免疫缺陷裸鼠模型中获得的结果可能与瘤型麻风患者可能得到的结果不可比。
